Dossier assessment
Nerandomilast (progrediente pulmonale Fibrose) – Nutzenbewertung gemäß § 35a SGB V
Report documents
-
Extract of dossier assessment
Nerandomilast (progrediente pulmonale Fibrose) – Nutzenbewertung gemäß § 35a SGB V
-
Dossier assessment
Nerandomilast (progrediente pulmonale Fibrose) – Nutzenbewertung gemäß § 35a SGB V
Dossier assessment
Indication:
Adults with progressive pulmonary fibrosis (PPF)
Result of dossier assessment:
- Nerandomilast as add-on therapy to ongoing nintedanib therapy: hint of minor added benefit
- Nerandomilast as add-on therapy to newly initiated nintedanib therapy or as monotherapy: added benefit not proven (no suitable data)
Project details
- Project no.
- A26-103
- Commission
- Commission awarded on 14.08.2026 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Airways and respiratory system
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://doi.org/10.60584/A26-103
Connected Projects
-
Dossier assessment
Nerandomilast (idiopathic pulmonary fibrosis) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed